Welcome to our dedicated page for Zoetis news (Ticker: ZTS), a resource for investors and traders seeking the latest updates and insights on Zoetis stock.
Zoetis Inc. reports developments as a global animal health company serving veterinarians, livestock producers and pet owners. Its updates center on medicines, vaccines, diagnostics, biopharmaceuticals and digital solutions for companion animals and livestock, organized commercially through U.S. and International segments.
Recurring news includes quarterly results and guidance, dividend declarations, investor conference presentations, pipeline and product-regulatory updates, and portfolio activity tied to animal health innovation. Company materials also describe R&D work across areas such as chronic kidney disease, oncology, cardiology, anxiety and obesity, as well as approved long-acting osteoarthritis pain products Lenivia and Portela.
On July 7, 2020, Trianni and Zoetis announced a collaboration to develop transgenic monoclonal antibody platforms aimed at discovering new veterinary treatments. This partnership is expected to leverage Trianni's advanced technology, which focuses on generating fully-human monoclonal antibodies, thus enhancing Zoetis' product development initiatives. The companies believe this collaboration will accelerate the creation of innovative therapeutics for animal health. No financial details regarding the collaboration have been disclosed.